The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Looking at all the metrics used in this study randox is the worst, but novacyt are not in top half either unless I am getting it wrong. These 2 are most common names currently linked to phe on this board. Could novacyt lose out in new phe orders? I'm now down after first getting in at 127 so don't want it to be true but might explain why gold standard product does not have more big orders now?
As much as everyone want to herald another amazing rns it was lower than pretty much all predictions I've seen in the run up to the release here and elsewhere. Still think undervalued massively but can understand reaction. This is a share that is a hold for next month or 2 at least not an overnight multibagger.
"The kit shows a priming efficiency of over 90% if used under optimal conditions" quote from very favourable toned article in the Manila times, Philippines that valley Ford highlights on twitter. I thought novacyt was 100% at identifying under optimal conditions. I'm no medic but know there are a few on this board, can anyone explain the apparent difference?
Unlikely. The jump in sales in April came from 6 month deal signed with phe which accounted for vast majority of sales taken (not filled) that month. If Egypt deal was for 40,000 kits and not tests which I think it is we should see £30-50m sales I would think. Need big contracts like phe, possibly Egypt I think to have more security in customer demand moving forward. Phe contract was for "at least" 288000 a week and confident realised sales to them will be higher.
Down to the bone. It is great customer service and will hopefully help build up some repeat purchases etc which is great. I'm just surprised they can do it as every piece of news I can find would seem to suggest even if manufacturing 20m a month there should be more demand. I'm hoping for more 6 month orders. Share price seems to be suggesting there are some issues that this investor cannot see. That is all and offering such quick delivery indicates no backlog of orders which surprises me.
You calculations seem logical but about 75% of announced sales so far have been to one customer. We need more big orders like those and don't understand reasons why more such orders have not been placed/announced. The fact that they are promoting same/next day delivery actually worries me a bit as means demand is not so high it is causing a back leg and from what I understand, gold standard etc it surely should. I'll be content with anything above £30m in contract sales, very happy anything above £50m
£90m a month ago, had Egypt deal announced by uk govt which was wierd but that should be £30-35m, still no news of WHO order or USA figures. Got to surely be £130m minimum which surely nudges sp in right direction but any other projections.
Novacyt have scaled up from 250,000 tests a month, to 2m, to 4m, 8m and now in june 10m+. Tests cost about £8.70 profit is 50%. Had £9m in bank as of end of April. Selling 288000 tests minimum a week to phe for 6 months, plus upto 30,000 per week to gsk/astra lab, 3.84m tests sent to Egypt. FDA, WHO, + 14+ other countries approved. 3 more products imminent .